A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Ipatasertib (Primary)
  • Indications Gastrointestinal cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 18 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to completed.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top